Literature DB >> 27884928

MACRA 2.0: are you ready for MIPS?

Joshua A Hirsch1, Andrew B Rosenkrantz2, Sameer A Ansari3, Laxmaiah Manchikanti4,5, Gregory N Nicola6,7.   

Abstract

The annual cost of healthcare delivery in the USA now exceeds US$3 trillion. Fee for service methodology is often implicated as a cause of this exceedingly high figure. The Affordable Care Act created the Center for Medicare and Medicaid Innovation (CMMI) to pilot test value based alternative payments for reimbursing physician services. In 2015, the Medicare Access and CHIP Reauthorization Act (MACRA) was passed into law. MACRA has dramatic implications for all US based healthcare providers. MACRA permanently repealed the Medicare Sustainable Growth Rate so as to stabilize physician part B Medicare payments, consolidated pre-existing federal performance programs into the Merit based Incentive Payments System (MIPS), and legislatively mandated new approaches to paying clinicians. Neurointerventionalists will predominantly participate in MIPS. MIPS unifies, updates, and streamlines previously existing federal performance programs, thereby reducing onerous redundancies and overall administrative burden, while consolidating performance based payment adjustments. While MIPS may be perceived as a straightforward continuation of fee for service methodology with performance modifiers, MIPS is better viewed as a stepping stone toward eventually adopting alternative payment models in later years. In October 2016, the Centers for Medicare and Medicaid Services (CMS) released a final rule for MACRA implementation, providing greater clarity regarding 2017 requirements. The final rule provides a range of options for easing MIPS reporting requirements in the first performance year. Nonetheless, taking the newly offered 'minimum possible' approach toward meeting the requirements will still have negative consequences for providers. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Entities:  

Keywords:  Economics

Mesh:

Year:  2016        PMID: 27884928     DOI: 10.1136/neurintsurg-2016-012845

Source DB:  PubMed          Journal:  J Neurointerv Surg        ISSN: 1759-8478            Impact factor:   5.836


  4 in total

1.  The Qualified Clinical Data Registry: A Pathway to Success within MACRA.

Authors:  M M Chen; A B Rosenkrantz; G N Nicola; E Silva; G McGinty; L Manchikanti; J A Hirsch
Journal:  AJNR Am J Neuroradiol       Date:  2017-05-18       Impact factor: 3.825

2.  Identifying Falls Risk Screenings Not Documented with Administrative Codes Using Natural Language Processing.

Authors:  Vivienne J Zhu; Tina D Walker; Robert W Warren; Peggy B Jenny; Stephane Meystre; Leslie A Lenert
Journal:  AMIA Annu Symp Proc       Date:  2018-04-16

3.  Who Will Pay for AI?

Authors:  Melissa M Chen; Lauren Parks Golding; Gregory N Nicola
Journal:  Radiol Artif Intell       Date:  2021-03-03

4.  Variation in Radiologic and Urologic Computed Tomography Interpretation of Urinary Tract Stone Burden: Results From the Registry for Stones of the Kidney and Ureter.

Authors:  David T Tzou; Dylan Isaacson; Manint Usawachintachit; Zhen J Wang; Kazumi Taguchi; Nancy K Hills; Ryan S Hsi; Benjamin A Sherer; Shalonda Reliford-Titus; Brian Duty; Jonathan D Harper; Mathew Sorensen; Roger L Sur; Marshall L Stoller; Thomas Chi
Journal:  Urology       Date:  2017-10-13       Impact factor: 2.649

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.